PEPTIDEREPORT

Video claim watch

Ozempic is a game-changer. Here's how it works.

Massive-view (3.5M+) mainstream explainer on Ozempic/semaglutide. Key signal for public understanding and claim patterns.

Vox channel8:00 runtime3.6M views when checked

Published Jan 1, 2023. Metadata checked Jul 1, 2026.

Watch on YouTube

Transcript review

5 material claims logged

Published with source gaps audit stateauto-captioned transcript0 operational-guidance flags1 source gap

Reviewed Jul 12, 2026. Next review Aug 12, 2026.

influential mainstream explainer with a key brand/indication distinction and one overstatement.

auto-caption available; no chapters.

Claim-by-claim audit

What the video says, and what needs checking

00:00:00
High-risk regulatory claim

correctly states Ozempic was FDA-approved for type 2 diabetes and notes weight loss.

Review topic: semaglutide brands/indications.

Checked against: Wegovy prescribing information

Ozempic label and R-GLP-2.

00:02:42
High-risk mechanism claim

explains semaglutide as a GLP-1 analogue affecting insulin/glucagon, gastric emptying, and CNS appetite signaling.

Review topic: mechanism.

Checked against: Wegovy prescribing information

00:04:46
High-risk evidence claim

says this effectiveness “rivals” metabolic bariatric surgery.

Review topic: comparative efficacy.

Checked against: Primary-source record still needed

surgery-specific comparative evidence; avoid cross-trial equivalence.

Connected research

Compounds discussed

Semaglutide Semaglutide is a GLP-1 receptor agonist sold as Ozempic, Wegovy, and Rybelsus for specific FDA-approved indications. Randomized trials support diabetes and chronic weight-management uses. Off-label, compounded, and broader behavioral claims require separate evidence and regulatory review.

Source check

Records used in this claim audit